Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Chris Markoch

Earnings Miss? Amgen’s Dividend Still a Bright Spot

Amgen Inc. (NASDAQ: AMGN) stock is down about 1.4% in after-hours trading despite beating estimates on the top and bottom lines in its fourth quarter 2024 earnings report. Investors appear to be selling the news on the company’s latest obesity drug, AMG-513, which was placed on a clinical hold by the FDA. The drug entered Phase 1 trials late in 2024.

As for the report itself, Amgen reported earnings per share (EPS) of $5.31 on revenue of $9.09 billion. Both numbers beat analysts’ estimates for an EPS of $5.08 on revenue of $8.88 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.